ProCE Banner Activity

HCC in the Setting of Hepatitis B: Asia-Pacific Considerations

Text Module

Learn from Grace LH Wong, MD, about prevention and treatment of HBV-related HCC in the Asia-Pacific region, where more than 75% of the global population with HBV resides.

Released: June 08, 2021

Expiration: June 07, 2022

Share

Faculty

Grace LH Wong

Grace LH Wong, MD

Professor
Gastroenterology and Hepatology
Assistant Dean (Learning Experience)
Director
CUHK Medical Data Analytics Centre (MDAC)
Faculty of Medicine
The Chinese University of Hong Kong
Hong Kong, China

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Gilead Sciences, Inc.

Target Audience

This program is intended for physicians, pharmacists, and other healthcare providers caring for patients with or at risk of HCC in the setting of hepatitis B.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify HBV-infected individuals at high risk for HCC development
  • Apply APASL guideline–based strategies for HCC screening among appropriate HBV-infected candidates in the Asia-Pacific region
  • Develop interdisciplinary strategies for diagnosing and managing HCC in the setting of hepatitis B in the Asia-Pacific region

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Grace LH Wong, MD

Professor
Gastroenterology and Hepatology
Assistant Dean (Learning Experience)
Director
CUHK Medical Data Analytics Centre (MDAC)
Faculty of Medicine
The Chinese University of Hong Kong
Hong Kong, China

Grace LH Wong, MD, has disclosed that she has received funds for research support from AbbVie and Gilead Sciences, consulting fees from Gilead Sciences and Janssen, and fees for non-CME/CE services from Abbott, AbbVie, Bristol-Myers Squibb, Echosens, Furui, Gilead Sciences, Janssen, and Roche.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no relevant conflicts of interest to report.

Jennifer Swanson, MEd

Associate Managing Editor, Hematology/Oncology
Clinical Care Options, LLC

Jennifer Swanson, PharmD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Program Medium

This program has been made available online.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Goal


The goal of this activity is to improve clinicians’ understanding of HCC risk in patients with hepatitis B and their competence in HCC screening, diagnosis, and comanagement with oncologists.